APHP

Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use

Retrieved on: 
Monday, March 11, 2024
Health Technology, Technology, Nanotechnology, Pharmaceutical, Oncology, Professional Services, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Data Analytics, Health, Research, WGS, Nephrology, APHP, STR, Single-nucleotide polymorphism, Partnership, CFH, Patient, Chelsea Handler, RUO, HPO, Oxford Nanopore Technologies, Thrombotic microangiopathy, Developed country, Nanopore sequencing, Thrombosis, CNV, Pharmaceutical industry

Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.

Key Points: 
  • Designed to streamline whole genome variant interpretation at scale, SeqOne DiagAi (RUO) saves time and reduces costs by ranking, shortlisting, and suggesting causative variants with best-in-class accuracy.
  • It also enables one-click HPO extraction from clinical notes with the DiagAI Notes2HPO large language model.
  • In the future, the collaboration will deliver other variant interpretation applications addressing the needs of cancer predisposition and somatic analysis.
  • “We are excited to collaborate with SeqOne to provide end-to-end solutions for our customers in rare disease and oncology.

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023
SCD, Database, Polymerization, Recherche, Sickle cell disease, Partnership, Thalassemia, Risk, AP-HP, Death, Hemolytic anemia, Research, B cell, Basophil, VOC, FYN, Assistance, Mortality, Health, Disease, Acute chest syndrome, KIT, RBC, Mouse, Human, Life expectancy, Investment, Euronext, SCIENCE, Inflammation, Patent, Science, CELL, Public, Biomarker, Toxicity, RHU, Histamine, Child, Patient, APHP, Substance P, LYN, ACS, Pharmaceutical industry

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Retrieved on: 
Saturday, December 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Fever, Bispecific monoclonal antibody, Research, NYSE, Injection site reaction, ASH, CRS, Risk, Disease, Fatigue, Patient, Abstract, PFS, MRD, AbbVie, Follicular lymphoma, COVID-19, Exposition, Neutropenia, ORR, University of Paris, Diarrhea, APHP, ABBV, Society, Overalls, Lymphoma, Cytokine release syndrome, Pharmaceutical industry

An estimated 85 percent and 74 percent of patients who experienced a CR remained in response at 12 and 18 months, respectively.

Key Points: 
  • An estimated 85 percent and 74 percent of patients who experienced a CR remained in response at 12 and 18 months, respectively.
  • Safety findings were consistent with previous epcoritamab trials, and epcoritamab was generally well tolerated.
  • TEAEs leading to treatment discontinuation occurred in 19 percent of patients, and Grade 5 TEAEs occurred in 13 patients (10 percent).
  • “The data presented at ASH reinforce what we have seen from our epcoritamab research and believe that this investigational bispecific antibody could potentially represent an important treatment option for patients living with relapsed or refractory follicular lymphoma.

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatology, INSERM, Immunity, Interferon, Immune system, ALT, HDV, HBsAg, AASLD, Clinical trial, Viral hepatitis, EOT, Patient, Small RNA, Abstract, Week, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, Peginterferon-alfa, CHD, APHP, Hepatitis, Vir, RNA, Vaccine, Pharmaceutical industry, Communications satellite, Treatment, Medicine

To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.

Key Points: 
  • To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.
  • “Chronic hepatitis delta is the most aggressive form of viral hepatitis.
  • Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Friday, November 10, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hepatology, INSERM, Interferon, AASLD, Viral hepatitis, Patient, EOT, Abstract, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, CHD, APHP, Hepatitis, Vaccine, Treatment, Medicine, Boston

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023.
  • These include one late-breaking poster presentation and one late-breaking oral presentation.
  • Title: VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks of Therapy (March Study Part B) (Abstract #48500)
    Presenter: Edward Gane, M.D., Professor of Medicine at the University of Auckland, New Zealand, and Chief Hepatologist, Transplant Physician and Deputy Director of the New Zealand Liver Transplant Unit at Auckland City Hospital
    Title: The Monoclonal Antibody VIR-3434 And siRNA VIR-2218 for the Treatment of Chronic Hepatitis D Virus: Preliminary Results from the Phase 2 SOLSTICE Trial (Abstract #5004)
    Presenter: Tarik Asselah, M.D., Ph.D., Professor of Hepatology at the Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, and Head of Viral Hepatitis at INSERM UMR1149, France
    Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Retrieved on: 
Saturday, December 9, 2023
Fever, NYSE, Cytokine release syndrome, Injection site reaction, Food, European Medicines Agency, Type, Incidence, Lymphoid leukemia, ASH, CRS, Disease, Risk, Clinical trial, Hematology, Fatigue, EMA, Patient, European, BTD, Data analysis, FDA, AbbVie, Follicular lymphoma, COVID-19, Neutropenia, ORR, University of Paris, Diarrhea, Death, APHP, ABBV, Genmab, Pharmaceutical industry

NORTH CHICAGO, Ill., Dec. 9, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with two or more prior therapies experienced strong and durable responses with high overall response (ORR) and complete response (CR) rates when treated with epcoritamab (DuoBody® CD3xCD20), an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the study remained responsive to treatment at the time of data analysis (i.e., median duration of response was not reached). Data from the dose-expansion cohort of the Phase 1/2 EPCORE™ NHL-1 clinical trial are being shared during a poster presentation on Saturday, December 9 at 5:30 PM PT at the ASH congress in San Diego, California. Updated data from this study include an optimized, step-up dosing schedule showing reduced incidence and severity of cytokine release syndrome (CRS), a notable side effect from immune-engaging cancer treatments.

Key Points: 
  • More than half of patients who responded to treatment in the study remained responsive to treatment at the time of data analysis (i.e., median duration of response was not reached).
  • "These data at this year's ASH further build our confidence in epcoritamab's treatment potential as well as development for earlier patient treatment."
  • An estimated 85% and 74% of patients who experienced a CR remained responsive to treatment at 12 and 18 months, respectively.
  • TEAEs leading to treatment discontinuation occurred in 19% of patients, and death related to TEAEs occurred in 13 patients (10%).

American Picture House Corporation Announces Uplisting to OTCQB Market

Retrieved on: 
Tuesday, November 7, 2023
Security (finance), OTC, OTC Markets Group, APH, APHP, OTCQB, Picturehouse, LOS

NEW YORK, NY, RALEIGH, NC, and LOS ANGELES, CA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –American Picture House (OTC:  APHP) is an entertainment company with a focus on producing feature films and limited series shows, and developing content-enhancing entertainment technologies, today announced its successful uplisting from the OTC Pink Market to the OTCQB effective November 8, 2023.

Key Points: 
  • NEW YORK, NY, RALEIGH, NC, and LOS ANGELES, CA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –American Picture House (OTC:  APHP) is an entertainment company with a focus on producing feature films and limited series shows, and developing content-enhancing entertainment technologies, today announced its successful uplisting from the OTC Pink Market to the OTCQB effective November 8, 2023.
  • The OTCQB is operated by the OTC Markets Group and recognized by the Securities and Exchange Commission ("SEC") as an established public market providing data to investors to analyze, value and trade securities.
  • Being part of the OTC Markets Group will assist in diversifying the APH shareholder base worldwide.
  • As of tomorrow, we are proud to start trading our common shares on the OTCQB Venture Market," said Michael Macgregor, CEO of American Picture House Corporation.

MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EBMT, Partnership, CIMON, ASH, ICI, DSMB, Head, European Medicines Agency, Survival, Charcot disease, Clinical trial, Cancer, SITC, Immunotherapy, Maat, EMA, Development, ARES, Investigational New Drug, PICASSO, Patient, CGMP, Microbiome, Lifting, MET, European Society for Medical Oncology, APHP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, IND, Food, Pharmaceutical industry, Nursing, Rare-earth element, Management, HSCT, Alexis de Tocqueville, ALS

Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.

Key Points: 
  • Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.
  • In June 2023 , MaaT Pharma also announced the appointment of Guilhaume Debroas as Head of Investor Relations.
  • As a post period event, in July 2023 , MaaT Pharma announced joining the Microbiome Therapeutics Innovation Group (MTIG).
  • The key unaudited financial results for the first half of 2023 are as follows:

American Picture House Corporate Update

Retrieved on: 
Wednesday, September 6, 2023
SURVIVOR, Coastal Maine Botanical Gardens, Writers Guild, TEXAS, SECRET, United States Housing Corporation, Screen Actors Guild, ASK, SAG, CIA, OTC, HATE, 2007–08 Writers Guild of America strike, LOS, APHP, House, Film industry, John Luessenhop

American Picture House supports the ideals behind the two current industry strikes -- brought by the Writers Guild of America (“WGA”) and the Screen Actors Guild (“SAG”) -- and joins the many reasonable voices urging for a fair and timely resolution.

Key Points: 
  • NEW YORK, NY, RALEIGH, NC, and LOS ANGELES, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – American Picture House Corporation (OTC: APHP), an entertainment company with a focus on producing feature films, limited series, and entertainment enhancing technologies, today provided a corporate update for shareholders.
  • American Picture House supports the ideals behind the two current industry strikes -- brought by the Writers Guild of America (“WGA”) and the Screen Actors Guild (“SAG”) -- and joins the many reasonable voices urging for a fair and timely resolution.
  • American Picture House commenced preproduction on two feature films, ASK CHRISTINE and DEVIL’S HALF ACRE.
  • American Picture House intends to announce a full slate of films later this year, including production of THE SECRET WAR, an historical-war drama based on CIA heroes in Laos during the Vietnam era, co-written by William J. Macdonald ( ROME , THE SAINT ) and John Luessenhop, to be directed by Luessenhop.

American Picture House Announces Filing of Form 10 Registration Statement

Retrieved on: 
Thursday, August 17, 2023
SAINT, Private equity, Executive, IPO, BBC, HBO, Dun, Venture capital, Robert Knox (private equity investor), Picturehouse, Intelligence, Fordham University School of Law, D&B, Sale, Georgetown University, Dun & Bradstreet, Privatization, Acquisition, JADE, Form 10-K, OTC, APH, CFO, AN, Knowledge, LOS, APHP, House, NYSE, Television, D, Film industry

NEW YORK, NY, RALEIGH, NC, and LOS ANGELES, CA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – American Picture House (OTC: APHP) is an entertainment company with a focus on producing feature films, television series, and content-enhancing entertainment technologies, today announced that a Form 10 registration statement was filed with the U.S. Securities and Exchange Commission (“SEC”). The Form 10 includes detailed information about American Picture House Corp., such as historic financial information, a description of its business and strategy, and other legal and financial disclosures.

Key Points: 
  • The Form 10 includes detailed information about American Picture House Corp., such as historic financial information, a description of its business and strategy, and other legal and financial disclosures.
  • American Picture House welcomes the appointment of Mr. Thomas Rauker and Mr. William J. Macdonald to its Board of Directors.
  • "We are pleased to welcome Thomas and Bill to the Board of APH," said Bannor Michael Macgregor, Chief Executive Officer of APH.
  • "Mr. Rauker provides deep executive leadership and Mr. Macdonald offers APH a wealth of knowledge in the entertainment industry.